Around one in five people globally suffer from chronic liver disease,1 despite 90% of cases being preventable.2
This usually undetected disease silently progresses to HCC, the third leading cause of cancer death.3,4
If something doesn’t change, it is predicted that deaths from liver cancer will more than double by 2040.4
Roche’s ONE Liver mission is to break this cycle, to help stop, or even reverse the disease, and our ambition is to one day cure it.
Our core expertise will continue to focus on cutting-edge diagnostics and treatment. To enable greater impact, partnerships are key.
We want to work together with liver specialists, researchers and patient organisations on ambitious programmes across the disease continuum to prevent progression and ultimately save lives.
1. Cheemerla S. and Balakrishnan M. Clin Liver Dis (Hoboken) 2021;17:365–370.
2. Macpherson I, et al. Frontline Gastroenterol 2022;13:367–373.
3. McGlynn KA, et al. Hepatology 2021;73(Suppl 1):4–13.
4. Sung H, et al. CA Cancer J Clin 2021;71:209–249.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.
This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.